NCT03956615 · OUTCOME

Amount of Paraprotein-targeting sdAbs Generated Per Patient

sdAb-based TRNT of Multiple Myeloma: a Feasibility Study · Source last updated 2021-12-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: unique sdAbs
Interval / dispersion: Not reported
Time frame: Within 2 years after study completion

What was measured

Absolute amount of unique sdAbs obtained per patient

Analysis population: Per participant, the number of different SdAb generated are reported.

Groups in this outcome

Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.

Only 1 arm/group in this trial

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.	3

Reported measurements

number of different SdAb for subject 1

Analysis denominator · Participants

Group	Source count
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.	1

Values in unique sdAbs · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.	14	Not reported	Not reported	Not reported	Not reported

number of different SdAb for subject 2

Analysis denominator · Participants

Group	Source count
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.	1

Values in unique sdAbs · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.	0	Not reported	Not reported	Not reported	Not reported

number of different SdAb for subject 5

Analysis denominator · Participants

Group	Source count
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.	1

Values in unique sdAbs · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.	20	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
14
denoms
counts
group Id
OG000
value
1
units
Participants
title
number of different SdAb for subject 1
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
1
units
Participants
title
number of different SdAb for subject 2
categories
measurements
group Id
OG000
value
20
denoms
counts
group Id
OG000
value
1
units
Participants
title
number of different SdAb for subject 5

denoms

counts
group Id
OG000
value
3
units
Participants

description

Absolute amount of unique sdAbs obtained per patient

groups

description
Only 1 arm/group in this trial
id
OG000
title
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.

param Type

NUMBER

population Description

Per participant, the number of different SdAb generated are reported.

reporting Status

POSTED

time Frame

Within 2 years after study completion

title

Amount of Paraprotein-targeting sdAbs Generated Per Patient

type

PRIMARY

unit Of Measure

unique sdAbs

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice